
Symbol Search

or enter GC* - Gold Futures

Quotes and Charts

YOU ARE HERE: Stocks » Quotes and Charts » News Headlines

Pfizer (PFE)

28.96-0.29 (-0.99%) 7:21P EDT (NYSE)

Price Quote as of Saturday, May 18th, 2013

Latest Pfizer (PFE) Headlines

Most active New York Stock Exchange-traded stocks

AP - Fri May 17, 5:06PM CDT

NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading: (full story)

Final Glance: Pharmaceuticals companies

AP - Fri May 17, 5:03PM CDT

NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)

Most active New York Stock Exchange-traded stocks

AP - Fri May 17, 12:36PM CDT

NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.: (full story)

Midday Glance: Pharmaceuticals companies

AP - Fri May 17, 12:33PM CDT

NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.: (full story)

Early Glance: Pharmaceuticals companies

AP - Fri May 17, 9:26AM CDT

NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)

Most active New York Stock Exchange-traded stocks

AP - Thu May 16, 5:05PM CDT

NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading: (full story)

Final Glance: Pharmaceuticals companies

AP - Thu May 16, 5:03PM CDT

NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)

Halozyme rises on pancreatic cancer drug study

AP - Thu May 16, 3:41PM CDT

NEW YORK (AP) — Shares of Halozyme Therapeutics Inc. climbed Thursday after the company reported clinical trial data for an experimental cancer drug. (full story)

Most active New York Stock Exchange-traded stocks

AP - Thu May 16, 12:31PM CDT

NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.: (full story)

Midday Glance: Pharmaceuticals companies

AP - Thu May 16, 12:29PM CDT

NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.: (full story)

Finding the Next Big Blockbuster Drug

ACCESSWIRE-TNW - Thu May 16, 10:21AM CDT

The pharmaceutical industry is largely centered on blockbuster drugs, with the top 20 drugs in the U.S. accounting for nearly $320 billion in sales in 2011. With five of those 20 drugs losing patent protection since then, there has been a high premium placed on finding the next big blockbuster drug on the part of companies and investors in the pharmaceutical industry. (full story)

Injury Law Firm Releases Up-to-Date Informational Graphic Regarding the Alleged Risks of the Popular Antibiotic Zithromax

PRWeb - Thu May 16, 9:54AM CDT

Zithromax (azithromycin), commonly known as Z-Pak, is one of the world's best-selling antibiotics used to treat and prevent certain bacterial infections including bronchitis, ear infections, pneumonia, and strep throat. The World Intellectual Property Organization (WIPO) reported in June 2003 that following the Zithromax patenting in 1981, Pfizer Inc. entered into a licensing agreement to further commercialize the drug, which has since produced over $1 billion annually from sales in the United States (i). (full story)

Early Glance: Pharmaceuticals companies

AP - Thu May 16, 9:36AM CDT

NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)

FDA Approves APOQUEL(R) (oclacitinib tablet) to Control Itch and Inflammation in Allergic Dogs

Business Wire - Thu May 16, 7:01AM CDT

Zoetis, Inc. (NYSE: ZTS), formerly the animal health business unit of Pfizer Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved APOQUEL(R) (oclacitinib tablet) for the control of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age. Pruritus, or itching, is the most common sign of allergies in dogs. Developed by Zoetis, APOQUEL is the first Janus kinase (JAK) inhibitor approved for veterinary use that targets the itch and inflammation pathway. APOQUEL provides fast-acting relief from itching and improves inflammation for the estimated 8.2 million dogs that suffer from short- and long-term allergic skin conditions. (full story)

Pharmaceutical-Biotech Industry to Pull Plug on 30 North American Sites in 2013, an Industrial Info News Alert

Marketwire - Thu May 16, 5:15AM CDT

Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- In a case of bad news being not quite as bad as it could be, the Pharmaceutical-Biotech Industry is forecast to shed 30 sites across North America during 2013. Eighteen already have closed, and the remainder are targeted to end operations by the end of December. (full story)

Most active New York Stock Exchange-traded stocks

AP - Wed May 15, 5:04PM CDT

NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading: (full story)

Final Glance: Pharmaceuticals companies

AP - Wed May 15, 5:02PM CDT

NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading: (full story)

Most active New York Stock Exchange-traded stocks

AP - Wed May 15, 12:27PM CDT

NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.: (full story)

Midday Glance: Pharmaceuticals companies

AP - Wed May 15, 12:26PM CDT

NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.: (full story)

Wider-Than-Expected Loss at Athersys - Analyst Blog

Zacks Equity Research - Zacks Investment Research - Wed May 15, 10:00AM CDT

Athersys' first quarter 2013 adjusted net loss of 13 cents per share was wider than the Zacks Consensus Estimate of a loss of 10 cents. (full story)

Older Stories